155 related articles for article (PubMed ID: 26165155)
1. Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells.
Wu B; Wang S; De SK; Barile E; Quinn BA; Zharkikh I; Purves A; Stebbins JL; Oshima RG; Fisher PB; Pellecchia M
Chem Biol; 2015 Jul; 22(7):876-887. PubMed ID: 26165155
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system.
Barile E; Wang S; Das SK; Noberini R; Dahl R; Stebbins JL; Pasquale EB; Fisher PB; Pellecchia M
ChemMedChem; 2014 Jul; 9(7):1403-12. PubMed ID: 24677792
[TBL] [Abstract][Full Text] [Related]
3. Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate.
Salem AF; Wang S; Billet S; Chen JF; Udompholkul P; Gambini L; Baggio C; Tseng HR; Posadas EM; Bhowmick NA; Pellecchia M
J Med Chem; 2018 Mar; 61(5):2052-2061. PubMed ID: 29470068
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Design of Novel EphA2 Agonistic Agents with Nanomolar Affinity in Vitro and in Cell.
Gambini L; Salem AF; Udompholkul P; Tan XF; Baggio C; Shah N; Aronson A; Song J; Pellecchia M
ACS Chem Biol; 2018 Sep; 13(9):2633-2644. PubMed ID: 30110533
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
6. Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine.
Quinn BA; Wang S; Barile E; Das SK; Emdad L; Sarkar D; De SK; Morvaridi SK; Stebbins JL; Pandol SJ; Fisher PB; Pellecchia M
Oncotarget; 2016 Mar; 7(13):17103-10. PubMed ID: 26959746
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery.
Chen X; Plasencia C; Hou Y; Neamati N
J Med Chem; 2005 Feb; 48(4):1098-106. PubMed ID: 15715477
[TBL] [Abstract][Full Text] [Related]
8. Cooperative dual-activity targeted nanomedicine for specific and effective prostate cancer therapy.
Yang HW; Hua MY; Liu HL; Tsai RY; Chuang CK; Chu PC; Wu PY; Chang YH; Chuang HC; Yu KJ; Pang ST
ACS Nano; 2012 Feb; 6(2):1795-805. PubMed ID: 22248493
[TBL] [Abstract][Full Text] [Related]
9. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
10. Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells.
Wang S; Placzek WJ; Stebbins JL; Mitra S; Noberini R; Koolpe M; Zhang Z; Dahl R; Pasquale EB; Pellecchia M
J Med Chem; 2012 Mar; 55(5):2427-36. PubMed ID: 22329578
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of paclitaxel to EphA2-expressing cancer cells.
Wang S; Noberini R; Stebbins JL; Das S; Zhang Z; Wu B; Mitra S; Billet S; Fernandez A; Bhowmick NA; Kitada S; Pasquale EB; Fisher PB; Pellecchia M
Clin Cancer Res; 2013 Jan; 19(1):128-37. PubMed ID: 23155185
[TBL] [Abstract][Full Text] [Related]
12. Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates.
Udompholkul P; Baggio C; Gambini L; Sun Y; Zhao M; Hoffman RM; Pellecchia M
Molecules; 2021 Jun; 26(12):. PubMed ID: 34204178
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
[TBL] [Abstract][Full Text] [Related]
14. Well-Defined Redox-Sensitive Polyethene Glycol-Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting.
Yin T; Wu Q; Wang L; Yin L; Zhou J; Huo M
Mol Pharm; 2015 Aug; 12(8):3020-31. PubMed ID: 26086430
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-assisted drug delivery.
Pilkington-Miksa M; Arosio D; Battistini L; Belvisi L; De Matteo M; Vasile F; Burreddu P; Carta P; Rassu G; Perego P; Carenini N; Zunino F; De Cesare M; Castiglioni V; Scanziani E; Scolastico C; Casiraghi G; Zanardi F; Manzoni L
Bioconjug Chem; 2012 Aug; 23(8):1610-22. PubMed ID: 22770429
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
17. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.
Ohman KA; Hashim YM; Vangveravong S; Nywening TM; Cullinan DR; Goedegebuure SP; Liu J; Van Tine BA; Tiriac H; Tuveson DA; DeNardo DG; Spitzer D; Mach RH; Hawkins WG
Oncotarget; 2016 Jun; 7(23):33529-41. PubMed ID: 27244881
[TBL] [Abstract][Full Text] [Related]
18. Tumor specific novel taxoid-monoclonal antibody conjugates.
Wu X; Ojima I
Curr Med Chem; 2004 Feb; 11(4):429-38. PubMed ID: 14965224
[TBL] [Abstract][Full Text] [Related]
19. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
Shi C; Cao H; He W; Gao F; Liu Y; Yin L
Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
[TBL] [Abstract][Full Text] [Related]
20. Targefrin: A Potent Agent Targeting the Ligand Binding Domain of EphA2.
Baggio C; Udompholkul P; Gambini L; Pellecchia M
J Med Chem; 2022 Nov; 65(22):15443-15456. PubMed ID: 36331527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
